Evidence map›Paper›PMID 42426800›Full record

ArticleJournal of nanobiotechnology2026

Tetrasulfide-bridged virus-like particles enable host-sparing cascade membrane-metabolic disruption for drug-resistant bacterial keratitis.

Wenlong Li, Qingdong Bao, Qinghua Li, Longfei Wang, Bingxin Ren, Hui Yan, Sihan Zhao, Fan Wu, Shunyao Jin, Hua Gao

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Wenlong LiState Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, Eye Institute of Shandong First Medical University, Qingdao, 266071, China. wlli@sdfmu.edu.cn.
Qingdong BaoState Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, Eye Institute of Shandong First Medical University, Qingdao, 266071, China.
Qinghua LiState Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, Eye Institute of Shandong First Medical University, Qingdao, 266071, China.
Longfei WangState Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, Eye Institute of Shandong First Medical University, Qingdao, 266071, China.
Bingxin RenState Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, Eye Institute of Shandong First Medical University, Qingdao, 266071, China.
Hui YanSchool of Ophthalmology, Shandong First Medical University, Jinan, 250001, China.
Sihan ZhaoSchool of Ophthalmology, Shandong First Medical University, Jinan, 250001, China.
Fan WuSchool of Ophthalmology, Shandong First Medical University, Jinan, 250001, China.
Shunyao JinSchool of Ophthalmology, Shandong First Medical University, Jinan, 250001, China.
Hua GaoState Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, Eye Institute of Shandong First Medical University, Qingdao, 266071, China. hgao@sdfmu.edu.cn.

Funding

Academic Promotion Program of Shandong First Medical University 2019RC009Major Basic research project of Natural Science Foundation of Shandong Province ZR2023ZD60National Natural Science Foundation of China 82371032, 82571179National Natural Science Foundation of China 82401219Natural Science Foundation of Shandong Province of China ZR2024QH257Shandong Province College Youth Innovation Team Project 2024KJJ014Taishan Scholar Program 20231255
6 · The paper itself

Abstract

Drug-resistant bacterial keratitis remains difficult to treat because anatomical barriers and biofilm-associated tolerance restrict antibacterial access and efficacy. Intensifying bactericidal activity can enhance bacterial clearance, but may also cause nonspecific host injury and disrupt stromal homeostasis. Thus, effective therapy requires a strategy that redirects antibacterial action from bacterial surface killing to intracellular intervention without perturbing the corneal stromal microenvironment. Herein, we developed AuNR@vTSMS-DLYS, a virus-mimetic spiky nanoplatform that couples bacterial barrier breaching with intracellular redox-metabolic disruption to achieve bacteria-selective eradication. Its spiky nanotopography enhances biofilm contact and disrupts membrane barriers, driving antibacterial intervention from the bacterial exterior into the intracellular space. Within the reductive bacterial intracellular milieu, the tetrasulfide-bridged framework is cleaved, glutathione is depleted, and sulfur overload is induced, thereby undermining intracellular bacterial defenses. Mild near-infrared irradiation provides spatially controllable photothermal amplification, further enhancing interfacial disruption, deep penetration, and intracellular damage. AuNR@vTSMS-DLYS achieved > 99% bacterial clearance in vitro and reduced corneal bacterial survival to 3.1% in a multidrug-resistant Pseudomonas aeruginosa keratitis mouse model, while restoring stromal thickness from 280 μm to 120 μm. This study establishes a host-sparing intracellular resistance-disarming strategy that redirects antibacterial action from bacterial external barriers to intracellular defense systems, offering a new design principle for precision treatment of drug-resistant infections.

Indexed as

Anti-Bacterial AgentsKeratitisSulfidesAnimalsBiofilmsCorneaDrug Resistance, BacterialMicePseudomonas aeruginosaPseudomonas InfectionsAnti-Bacterial AgentsSulfidesAntibiotic-free antibacterial strategyBacterial keratitisGlutathione depletionHost-sparingRedox-metabolic disruptionVirus-mimetic nanoplatform

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.